About Us

Overview

EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in pain management and cancer treatment. The Company possesses three major clinical product candidates, including:

• AmiKet™, a topical pain medication that has completed Phase II clinical trials.
• Crolibulin™, an apoptosis inducer for solid vascularized tumors that is currently in Phase Ib/II clinical trials.
• Azixa™, an oncology compound that is currently being assessed for possible future development.

In November 2012, EpiCept entered into a definitive merger agreement with Immune Pharmaceuticals Ltd (Immune) that is anticipated to close in August 2013.  The combined entity, to be named Immune Pharmaceuticals, Inc., will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.  Immune’s lead product candidate, bertilimumab, is a fully human monoclonal antibody that targets eotaxin-1, a chemokine involved in eosinophilic inflammation, angiogenesis and neurogenesis.  Immune is currently initiating a placebo-controlled, double-blind Phase II clinical trial with bertilimumab for the treatment of ulcerative colitis.

EpiCept is headquartered in Tarrytown, New York.

EpiCept is listed on both the Nasdaq OMX Stockholm Exchange and the OTCQX under the symbol “EPCT”.

Vision and Mission

EpiCept’s vision is to create and develop products that make a meaningful difference in people’s lives. As such, it is dedicated to successfully increasing the life span of cancer patients and continually improving the quality of life of pain sufferers.

Our mission is the relentless pursuit of satisfying unmet medical needs with pharmacologic agents that are based on sound scientific findings, demonstrated safety and efficacy, and unique and proven technologies. We are focused on advancing a pipeline of world-class products that treat malignant diseases and moderate-to-severe pain.

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company’s pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. The Company has oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

EpiCept seeks to generate significant value for its shareholders by developing effective drug candidates, including new chemical entities and new uses for existing therapies, advancing them into late-stage clinical development and then seeking marketing approval either alone or in conjunction with strategic partners.